Notably, the pretreatment primary tumor biopsy of our patient with lung cancer had an HRD-sum score of 25 that is higher than the median of 14 for BRCA1/2 mutated tumors at similar purity levels (Fig. 4D), further affirming the HRD phenotype of the pre-treatment lung tumor. The gene discussed is BRCA1; the disease is lung carcinoma.